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Introduction
Annual influenza epidemics globally cause significant 
morbidity and mortality [1]. High rates of influenza 
hospitalisations occur in healthy infants and young chil-
dren as well as in adults with risk factors, whereas most 
deaths occur in the elderly  [2-4]. In addition to annual 
epidemics, influenza virus causes occasional pandemics, 
which may have an extremely high burden worldwide. 
Secondary bacterial pneumonia represents an important 
cause of excess mortality during both influenza epidem-
ics and pandemics [5]. 
The lethal association between influenza and bacterial 
infections was first hypothesized from 1890 to 1950, 
when most observers believed fatal influenza to be 
a polymicrobial infection in which an inciting agent 
of low pathogenicity, most of which have now been 
identified as viruses, acted synergistically with known 
pneumopathogenic bacteria [5]. This synergism came 
into particular focus during the influenza pandemic of 
1918, when 40 to 50 million deaths occurred, many 
because of secondary bacterial pneumonia. In par-
ticular, recent studies, examining recut tissue speci-
mens and reviewing epidemiologic, pathologic, and 
microbiologic data, have highlighted the major role of 
Streptococcus pneumoniae (Sp) in determining excess 
mortality during the 1918 influenza pandemic [5, 6]. 
These findings have been recently confirmed by data 
collected during the 2009 A/H1N1v influenza pan-
demic [7-10]. 
Numerous studies, performed in animal model, demon-
strated that influenza A virus infection causes signifi-
cant changes in the respiratory tract, such as epithelial 
damage, alterations in airway function, up-regulation 
and exposure of receptors, and impairment of the in-
nate immune response, thus severely increasing sus-
ceptibility to secondary Sp infection [11-13]. The most 
important evidences that have suggested the lethal syn-
ergism between influenza virus and Sp, both in animal 
model and in human beings, are discussed below in 
the text.
Since 2000, a seven-valent pneumococcal conjugate 
vaccine (PCV7) was introduced in the US, and in the 
following year in Europe, determining substantial and 
almost immediate benefits in terms of reduction of in-
vasive pneumococcal disease (IPD) in both vaccinated 
children and adults through induction of herd protec-
tion [14-20]. During the last years, evidences of the 
positive impact of this vaccine on community-acquired 
pneumonia (CAP), in terms of reduction in the number 
of hospitalisations and ambulatory visits for all-cause 
pneumonia, have been also growing up in the litera-
ture [21-24]. This is of particular meaning considering 
the role of secondary bacterial infection as a major com-
plication of influenza. Furthermore, recent studies have 
demonstrated a significantly fewer influenza-associated 
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Summary
Secondary bacterial pneumonia, particularly sustained by Strep-
tococcus pneumoniae (Sp), represents an important cause of 
excess mortality during both influenza epidemics and pandemics. 
The lethal synergism between influenza virus and Sp was first sug-
gested by studies performed on samples collected during autopsy 
from victims of 1918 influenza pandemic, and recently confirmed 
by data collected during the 2009 A/H1N1v influenza pandemic. 
Moreover, researches carried out in animal model contributed to 
partially clarify the pathogenic mechanisms underlying the syner-
gism between these two etiological agents.
Since 2000, a seven-valent pneumococcal conjugate vaccine 
(PCV7) was introduced in the US, and in the following year in 
Europe, determining substantial and almost immediate benefits 
in terms of reduction of invasive pneumococcal disease (IPD) 
in both vaccinated children and adults through induction of 
herd protection. Furthermore, several researches have recently 
demonstrated the capacity of the PCV7 to prevent community-
acquired pneumonia (CAP) and, in particular, influenza-asso-
ciated pneumonia hospitalisations among children. Taking into 
account the above-mentioned positive results obtained with 
PCV7, the availability of a new generation of conjugate pneu-
mococcal vaccine with an enlarged antigenic spectrum (i.e. 
PCV13) offers promising perspectives, to improve the control 
of influenza through the protection offered against its major 
complications, particularly CAP, not only in children, but also 
among adults.
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pneumonia hospitalisations among children immunized 
with PCV7 [25, 26]. 
The availability of a new generation of conjugate pneu-
mococcal vaccines with an enlarged antigenic spectrum 
(i.e. PCV13), together with the positive results obtained 
with PCV7, as discussed below, offer promising per-
spectives to reduce the burden of influenza, improving 
the protection against its major complications, particu-
larly CAP, not only in children, but also among adults.
Influenza and Streptococcus pneumoniae 
sequential infections in animal model
Since seventies a correlation between influenza infec-
tion and severity of illness due to streptococcus was re-
ported in animal model.
Squirrel monkeys, inoculated intratracheally with in-
fluenza A virus (H3N2), responded with clinical illness 
including signs such as fever, sneezing or coughing, 
coryza, and increased respiratory rates. Necropsy stud-
ies performed six days after inoculation revealed bron-
chopneumonia in addition to a mild tracheitis. Squirrel 
monkeys infected with both influenza virus and Sp in-
tratracheally died four to six days later after develop-
ing severe illness characterized by fever, bacteraemia, 
lethargy, anorexia, coughing, laboured breathing, and 
bronchopneumonia. At necropsy these monkeys had 
more extensive and severe bronchopneumonia than 
was seen in monkeys infected with either organism 
alone [27].
More recently, studies performed in mice have contrib-
uted to elucidate the interaction between Sp and influen-
za. Mouse models showed that influenza infection pre-
ceding pneumococcal challenge primed for pneumonia 
and led to 100% mortality. Differently, reversal of the 
order of administration led to protection from influenza 
and improved survival. Findings of this study showed 
that influenza virus infection primes for development of 
lethal pneumococcal pneumonia with a dose dependent 
mechanism and that the effect is stronger if exposure to 
pneumococcal occurs seven days after influenza infec-
tion resulting in a more severe pathologic picture than 
a classic lobar pneumonia, otherwise if pneumococcal 
administration precedes influenza infection, survivals to 
this latter is improved. The meaning of this observation 
has still to be clarified [11]. 
A number of studies performed in animal model have 
contributed to partially clarify the pathogenic mecha-
nisms underlying the synergism between influenza virus 
and Sp: the main findings are summarized in Table I.
Influenza and Streptococcus 
pneumoniae: evidence from the past
Although a widespread conviction still exists, also 
among physicians, that the 1918 influenza had a fulmi-
nate course, led to death within hours or days as a result 
of acute respiratory distress syndrome (ARDS) directly 
caused by primary viral pneumonia, these events were 
an unusual characteristic in this pandemic, representing 
a small proportion of the fatal cases, yet. It has been es-
timated that less than 5% of deaths occurred within 3 
days after the onset of flu symptoms, while most deaths 
occurred within 7-14 days, and about 30% of deaths oc-
curred more than 14 days after initial symptoms [28]. 
The examination of recut lung tissue sections, obtained 
during autopsy from 58 influenza victims, revealed, in 
virtually all cases, compelling histologic evidence of se-
vere acute bacterial pneumonia, either as the predomi-
nant pathology or in conjunction with underlying patho-
logic features now believed to be associated with influ-
enza virus infection [5]. This study also examined the 
bacterial culture results of 96 post-mortem lung tissue 
culture series, which examined 5266 subjects, demon-
strating that 92.7% of autopsy lung cultures were posi-
tive for ≥ 1 bacterium and that Sp was the single most 
common infecting bacterium isolated [5].
In accordance with these findings, a recent review, which 
analysed the studies that had investigated more than 10 
sterile-site ante-mortem cultures from adults with pneu-
Tab. I. pathogenic mechanisms underlying the synergism between influenza virus and streptococcus pneumonia. 
Epithelial damage
increased exposure of binding sites for the bacterium (eg, elements of the basal 
membrane, such as fibrinogen)
Reduced activity in the 
mechanisms of airway protection
impaired ciliary function (decreased beat rate, non-coordinated activity)
impaired ciliary function (decreased beat rate, non-coordinated activity)
obstruction of small airways due to the destruction of the surfactant
increase in secretions of mucinous
Up-regulation and increased 
exposure of specific adhesion 
receptors of the bacterium
sialic acid cleavage by the viral na determines the exposure of receptors at the level of the 
lower airways that binds pneumococcus
pro-inflammatory cytokines up-regulate the expression of cellular receptors (eg pafr) that 
promote the adhesion of pneumococcus
Down-regulation of the innate 
immune response
increased interferon-γ: down regulation of scavenger receptor (marCo) of alveolar 
macrophages
influenza virus causes apoptosis (in vitro) and altered function (in vivo) of neutrophils
influenza virus impairs the activity of macrophages, reducing chemotaxis and by 
suppressing phagocytosis
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monia and those without pneumonia, showed that bac-
teria could be identified in only a few blood cultures for 
patients who had influenza but not pneumonia (mean 
among all the reports, < 1%), whereas these agents were 
isolated in 16% of samples collected from patients with 
influenza-associated pneumonia and in 40% of samples 
from patients who died. Moreover, 80% of pleural-fluid 
and lung cultures from patients with pneumonia yielded 
bacteria, and Sp was the most frequent bacterium iso-
lated, comprising 71% of positive cultures [6]. 
Therefore, bacteria were commonly recovered from hu-
man samples of living pneumonia cases and fatal cases 
in the 1918 pandemic, suggesting that these microbio-
logical agents, particularly Sp, played an important role 
in the pathogenesis of the influenza associated pneumo-
nia and death in this pandemic.
Influenza and Streptococcus pneumoniae: 
evidence from the 2009 A/H1N1V pandemic
In April 2009, novel swine-origin influenza A (H1N1) 
virus was identified in California and Mexico as a cause 
of human respiratory disease. On 11st June 2009, the 
World Health Organization (WHO) declared a pandemic 
outbreak of respiratory illness associated with this novel 
influenza virus.
Since in previous influenza pandemics studies of au-
topsy specimens have demonstrated that most deaths 
attributed to influenza A virus infection occurred con-
currently with bacterial pneumonia, several studies in-
vestigated the interaction between these microorganisms 
in the context of the last pandemic event. 
A report by Center for Disease Control and prevention 
(CDC) analysed samples from 77 US patients with fatal 
cases of confirmed 2009 pandemic influenza A/H1N1v, 
evidencing concurrent bacterial infection in 22 (29%) 
cases of the 77 patients, including 10 (45.5%) isolations 
of Sp [7].
A post mortem study reported the pathological findings 
from 21 patients with proven novel A/H1N1v infection 
who died during the winter period of the 2009 pandemic 
in Sao Paulo, Brazil, evidencing as the cause of death in 
all patients was extensive involvement of the lungs and 
founding evidence of bacterial coinfection in 8 (38.1%) 
out of 21 patients: in 6 (28.6%) patients bacteriological 
analysis by culture of bronchial aspirate and/or tissue 
PCR revealed Sp as the etiological agent [8]. 
A study, performed in 337 Argentinian adult patients 
with confirmed, probable, or suspected cases of 2009 
influenza A/H1N1v admitted to 35 Intensive Care Units 
with acute respiratory failure requiring mechanical ven-
tilation, demonstrated coexistent bacterial pneumonia 
on admission in 25% of the patients. Sp was isolated in 
35% of these subjects with bacterial coinfection and this 
pathogen was found to be associated with worst prog-
nosis, despite concurrent antibiotic treatment on admis-
sion [9].
Another Argentinian study examined nasopharyngeal 
swab samples from 199 cases of mild and severe influen-
za A/H1N1v infection, identifying at least one additional 
pathogenic agent importance in 152 (76%) samples. Sp 
was isolated in 62 (40.8%) out of the 152 positive sam-
ples and its presence was strongly correlated with severe 
disease also in this research [10].
Innovative perspectives of vaccine 
prevention
Influenza virus and Sp represent two of the most im-
portant pathogens affecting humans today in Western 
Countries, being public health priorities. The demon-
stration of their ability to work synergistically further 
evidences the need for improving strategies for the 
control of influenza and its most frequent complica-
tion, which is secondary bacterial pneumonia. 
Primary prevention of both influenza and Sp associat-
ed diseases is largely based on vaccination. In the last 
decades, the implementation of innovative strategies to 
improve the performance of influenza vaccines, name-
ly, the addition of different adjuvants (i.e., MF59- and 
AS03-vaccines, virosomal formulations), the use of al-
ternative routes of administration or manufacture (i.e., 
intradermal, nasal and oral vaccines and cell culture- and 
reverse genetic-based vaccines) or of high doses of anti-
gen, has contributed to substantially improve the protec-
tion conferred against the disease [29].
At the same time, the availability of pneumococcal con-
jugated vaccines has contributed to increase the protec-
tion against Sp associated diseases. In particular, the 
wide use of PCV7 in universal childhood vaccination 
programs, both in US and Europe, has determined a sig-
nificant and rapid impact on IPD in the target paediatric 
population: monitoring a sample of the US population of 
nearly 1.26 million subjects, nearly a 100% and a 76% 
reduction in IPD rates, as related to vaccine serotypes and 
to all Sp-types, were registered among children aged less 
than 5 years, comparing the pre- versus post-vaccination 
periods, with values declining from 81.9/105 to 0.4/105 
and from 98.7/105 to 23.6/105, respectively [15]. Simi-
lar findings, concerning the effects of the PCV7 against 
IPD, were also obtained in Europe and Canada, thus fur-
ther confirming the positive effects of the universal chil-
dren immunization campaign worldwide [16-20].
Surprisingly, the universal vaccination of newborns rap-
idly determined an indirect protection against IPD also 
among the non-vaccinated: notably, in 2003, the vaccine 
prevented more than twice as many IPD cases in the US, 
just through this indirect effect [14]. This positive effect 
persisted during the years following the introduction of 
the universal immunization program, and resulted par-
ticularly marked in subjects aged ≥ 65 years, a group 
at higher risk for IPD than the young adult population: 
comparing average data collected in 1998-1999 (base-
line) with those in 2007, a reduction in IPD rates of 37% 
and 92% was reported for all types and vaccine types, 
respectively [15].
Moreover, PCV7 has been demonstrated to be effective 
also for the prevention on non-invasive pneumococcal 
disease, particularly CAP. Data from the US Nationwide 
Inpatient survey system reported a 39% reduction in 
synergism between influenza and streptoCoCCus pneumoniae
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hospital admissions for all-cause pneumonia in children 
aged < 2 years, and of 75% of pneumonia with Sp as 
aetiological agent: this resulted in fewer 41.000 admis-
sions than the expected in the year 2004 [21]. These data 
are comparable with those reported in a recent survey, 
among children aged < 2 years, showing that the rate for 
all-cause pneumonia was approximately 35% lower in 
2006 than during the control period 1997-1999, with the 
values of 9.1 per 1,000 and 8.1 per 1,000, in the period 
2005-2006, respectively [22]. Another American study, 
comparing the pre-vaccination (1998-1999) and the post-
vaccination period (2004), demonstrated a reduction of 
52.4% and of 41.1% in the number of hospitalizations 
for all-cause pneumonia and of ambulatory visits for the 
same cause in young children, respectively [23].
Data obtained in Liguria, a North West Italian admin-
istrative Region, where PCV7 has been first introduced 
since 2003, are in accordance with the above mentioned 
results: during the period 2000-2007, a significant de-
cline in hospitalization rates, among children aged 0-24 
months, for all-cause and pneumococcal pneumonia 
(p < 0.05) was observed after the widespread immuniza-
tion, with preventive fractions of 15% and 70.5%, re-
spectively [24].
Recently, two studies, of particular interest, have inves-
tigated the capacity of pneumococcal conjugate vaccines 
to prevent hospitalisation for pneumonia in patients af-
fected with seasonal influenza. 
Madhi SA and colleagues, in a double-blind, rand-
omized, placebo controlled trial in 39,836 children, 
18,245 receiving all three doses of nine-valent pneumo-
coccal conjugate vaccine (PCV9) and 18,268 receiving 
placebo, demonstrated that PCV9 was able to prevent 
31% and 45% of hospitalisations for pneumonia associ-
ated with seven major respiratory viruses and influenza 
A virus, respectively [25]. 
An American research assessed the impact of infant 
immunization on pneumococcal pneumonia hospitali-
zations and mortality in all age groups using Health 
Care Utilization Project State Inpatient Databases 
(SID) from 1996 to 2006, in 10 US states. Compared to 
a 1996-1997 through 1998-1999 baseline, by the 2005-
2006 season, both IPD and pneumococcal pneumonia 
hospitalizations and deaths had decreased substantially 
in all age groups, including a 47% reduction in non-
bacteremic pneumococcal pneumonia in infants < 2 
years old and a 54% reduction in adults > 65 years of 
age. Furthermore it has been estimated that, from 2000 
to 2006, hospitalisations for pneumococcal pneumonia 
decreased of 788,838 cases: 90% of the reduction in 
pneumococcal pneumonia hospitalizations was attrib-
uted to the herd protection among adults 18 years old 
and older. Interestingly, in the first seasons after PCV7 
introduction, when there were substantial state differ-
ences in coverage among subjects < 5-year-olds, US 
states with greater vaccination coverage had signifi-
cantly fewer influenza-associated pneumonia hospital-
izations among children, suggesting that this vaccine 
might also reduce influenza-attributable pneumonia 
hospitalisations, presumably because of its ability to 
prevent pneumococcal pneumonia frequently follow-
ing influenza infection [26]. 
In Western Countries, deaths attributable to influenza 
has been significantly increased in the last 20 years, 
mainly due to the progressive aging of the population: in 
the frail elderly, the association of serious viral respira-
tory infections and bacterial co-infection, mainly attrib-
utable to Sp, represents a serious risk of death in these 
patients [4]. 
The positive results registered in children immunized 
with PCV7, in terms of protection against CAP and 
influenza-associated pneumonia, together with the pos-
sible availability of the new generation of pneumococcal 
conjugate vaccine (PCV13) in adults open interesting 
perspectives for improving the control of both Sp-asso-
ciated diseases and influenza.
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